Eton Pharmaceuticals(NASDAQ) ETON

Eton Pharmaceuticals, Inc. NASDAQ:ETON makes medicines for rare health conditions. These products help patients with few treatment options. Eton gets important therapies to people who need them.

A Portfolio for Rare Conditions

• Metabolic Health: Medications like Carglumic Acid, Betaine Anhydrous, and Nitisinone treat rare genetic disorders; sales of these products helped drive revenue growth in the first half of 2026.
• Hormone Treatments: Products including Alkindi Sprinkle and Khindivi manage adrenal insufficiency, while Increlex treats severe primary growth hormone deficiency.
• Infant Care: Hemangeol is used to treat proliferating infantile hemangioma, which is a type of non-cancerous tumor made of blood vessels.
• Nutrition and Support: PKU Golike provides medical food for phenylketonuria, a condition where the body cannot break down a specific amino acid.

Expanding the Treatment Pipeline

• Acquired the U.S. commercial rights to Hemangeol in February 2026 for a payment of $14 million.
• Licensed U.S. marketing rights for an ultra-rare disease product candidate in February 2026 with an upfront payment of $1 million.
• Received FDA approval for Desmoda in February 2026 following a New Drug Application filing in 2025.
• Scheduled the commercial launch of Impavido for September 2026 to further expand the rare disease portfolio.

Focusing on Specialized Medicine

Eton manages a broad portfolio of 11 commercial products with a workforce of 44 employees. The company focuses on the rare disease market by acquiring established treatments and developing its own product candidates.

Strong Revenue Momentum

• Total revenues reached $37.6 million for the three-month period ended June 30, 2026, compared to $18.9 million in the 2025 period.
• GAAP net income was $11.6 million for the three months ended June 30, 2026, improving from a net loss of $2.6 million in the prior year.
• Net cash from operating activities reached $14.7 million for the six months ended June 30, 2026.
• Market cap was $993.5 million in Q2 2026, up 159.2% year over year.

From Development to Profitability

Eton has evolved from a development-stage firm into a profitable commercial enterprise with a diverse range of rare disease treatments. Its strategy of acquiring product rights and securing new FDA approvals has significantly expanded its market presence.